



Heath Lukatch, Ph.D., Partner and Managing Director

Prior to joining TPG Biotech in 2015, Heath was a Partner at Novo Ventures (US), where he helped establish Novo Ventures' San Francisco office. During his 9 years at Novo, Heath served as Chairman of Cianna Medical, Inogen (INGN), NTP, and Spinifex Pharmaceuticals (acquired by Novartis in 2015). He served as a board member at Amira Pharmaceuticals (acquired by BMS in 2011), AnaptysBio, Elevation Pharmaceuticals (acquired by Sunovion in 2012), Flexion Therapeutics (FLXN), FoldRx Pharmaceuticals (acquired by Pfizer in 2010), InSound Medical (acquired by Sonova in 2010), Nora Therapeutics, and Synosia Therapeutics (acquired by BioTie in 2011), and was a board observer at Alios BioPharma (acquired by J&J in 2014). Prior to joining Novo, Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, where his investments included Dynavax (DVAX) and Fluidigm (FLDM). Before Piper Jaffray Ventures, he worked as a strategy consultant with McKinsey & Company, where he was a leader in McKinsey's biotechnology practice. Heath also served as Co-founder and CEO of AutoMate Scientific, a biotechnology instrumentation company, and he has held scientific positions with Chiron, Roche Bioscience, and Cetus, doing molecular biology, electrophysiology and protein chemistry, respectively. Heath received his Ph.D. in neuroscience from Stanford University, where he was a DOD USAF Fellow, and his B.A. with High Honors in Biochemistry from the University of California at Berkeley.



Eran Nadav, Ph.D., Partner and Managing Director

Eran joined TPG Biotech in 2007 to invest in global pharmaceuticals and biotechnology. He invests in a broad range of early- to late-stage companies and products, including innovative therapies and high value generics. Prior to TPG, Eran served as Business Development Director at Eisai, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this he worked for the Israeli office of JJDC, the venture capital subsidiary of Johnson & Johnson, where he analyzed and executed investments in innovative technologies and biopharmaceuticals. Previously, Dr. Nadav worked for Neurim Pharmaceuticals Ltd. supporting the clinical development of Circadin®. He holds a Ph.D. in biochemistry, M.Sc. Magna Cum Laude, B.Sc. Magna Cum Laude, and MBA - all from Tel Aviv University. Eran currently serves as Chairman of the Board of Trevi Therapeutics, and Board member at Collegium Pharmaceutical (COLL), ShangPharma (a China-based CRO), and NovaSom. He was the Chairman of the Board of Ultragenyx Pharmaceutical (RARE) from January 2012 to June 2015. Other past investments and Board roles include JCR Pharmaceuticals (a Japanese biopharma company; 4552), MacroGenics (MGNX), and Mayanot Eden.



Heather Preston, M.D., Partner and Managing Director

Heather Preston is a Firm Partner and Managing Director of TPG Biotech. Prior to joining TPG Biotech in May 2005, Dr. Preston spent two years at JP Morgan Partners where she focused on medical device and biotechnology venture capital investing. Prior to JP Morgan Partners, Dr. Preston was an Entrepreneur-in-Residence with New Enterprise Associates. She also spent five years at McKinsey & Co. in New York, where she was a leader of their pharmaceutical and medical products consulting practice. She advised large pharmaceutical companies and biotechnology companies on critical strategic issues such as R&D portfolio prioritization, M&A opportunities, new technology acquisitions, new product launches and product growth strategies.

Dr. Preston currently serves on the board of directors of Albireo, Inc. (ALBO); Alder BioPharmaceuticals (ALDR); Otonomy, Inc. (OTIC); Unchained Labs, Avalyn Pharmaceuticals, Azura Ophthalmics and Entasis Inc. She has previously served on multiple private boards including the boards of Aptalis Pharma (acquired by Forest Labs in 2014), and Elevation Pharmaceuticals (acquired by Sunovion in 2012). She was responsible for TPG Biotech's investment in Par Pharmaceuticals (acquired by Endo in 2015).

Dr. Preston has an undergraduate degree in biochemistry from the University of London and a medical degree from the University of Oxford. Dr Preston completed a post-doctoral fellowship in molecular biology at the Dana Farber Cancer Institute, Harvard University and trained in Internal Medicine at the Massachusetts General Hospital and sub-specialized in Gastroenterology and Hepatology at UCSF. During her academic medical career, she was the recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Fine Arts Museums of San Francisco, Saint Luke's School and the Harlech Scholarship Foundation. recipient of a Fulbright Scholarship, a Fulbright Cancer Research Scholarship, a Harlech Scholarship and a Science and Engineering Research Council Post-doctoral Fellowship Award. Dr. Preston also serves on the Board of Trustees for the Fine Arts Museums of San Francisco, Saint Luke's School and the Harlech Scholarship Foundation.



Peter Bojo, Associate

Prior to joining TPG Biotech in 2014, Peter worked in management consulting at Oliver Wyman for 3 years with projects including strategy and M&A engagements within healthcare and financial services. Prior to Oliver Wyman, he worked in R&D at a medical device startup. Peter has a Master's and a B.S. from M.I.T. in Bioengineering, has co-authored several papers, and is a member of Tau Beta Pi and Phi Beta Kappa honor societies.